Comparison Between Low and Medium Dose Radial Extracorporeal Shock Wave Therapy on Patients with Cervicogenic Headache: a Randomized Controlled Trial
Launched by MTI UNIVERSITY · Mar 13, 2025
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different doses of a treatment called radial extracorporeal shock wave therapy can help patients with cervicogenic headaches, which are headaches that start in the neck. The trial will compare two doses of shock wave therapy—one lower and one medium—along with exercises to strengthen and stretch the neck muscles. Participants will be randomly assigned to one of three groups: one will receive the lower dose of shock waves, another will get the medium dose, and the third will receive a placebo treatment that doesn’t involve real shock waves.
To be eligible for this trial, participants should have neck pain that has lasted for more than three months and specific symptoms like painful trigger points in their muscles and headaches that occur at least once a week. However, those with other types of headaches, such as migraines, or certain neck injuries or conditions will not be included. Participants can expect to have their progress monitored at the start and end of the treatment, and they will also be doing exercises to help with their neck pain. This trial aims to find out which dose of shock wave therapy is more effective for relieving pain and headaches.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Symptoms of mechanical neck pain lasting for more than three months
- • Skeletal muscle with a palpable taut band
- • Hypersensitive point inside the taut band with the ability to reproduce referred pain when the sensitive spot is palpated,
- • Joint soreness in at least one of the upper cervical spine's joints (c1-c3)
- • Unilateral discomfort that originates in the neck and radiates to the frontotemporal area
- • Pain that is made worse by moving the neck
- • Headaches that occur at least once a week for a duration longer than three months.
- Exclusion Criteria:
- • Other primary headaches (i.e., migraine, tension-type headache)
- • Bilateral headaches,
- • Other defined cervical problem such as fracture, dislocation, skin disease, illness that is inflammatory, neural illness, vertebrobasilar insufficiency, a birth defect, tumor, or infection.
About Mti University
MTI University is a leading academic institution dedicated to advancing healthcare and medical research through innovative clinical trials. Committed to fostering collaboration between academic researchers and industry partners, MTI University focuses on developing cutting-edge therapies and technologies aimed at improving patient outcomes. With a robust infrastructure and a team of experienced professionals, the university prioritizes ethical standards and regulatory compliance in its research endeavors, ensuring the highest quality of care and safety for participants. As a sponsor, MTI University is dedicated to contributing valuable insights to the scientific community and enhancing the overall landscape of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported